Research programme: bacterial topoisomerase inhibitors - Redx Pharma

Drug Profile

Research programme: bacterial topoisomerase inhibitors - Redx Pharma

Alternative Names: NBTIs; REDX06213; REDX06276; REDX07623

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator Redx Pharma
  • Class Antibacterials; Small molecules
  • Mechanism of Action Type II bacterial DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 16 Jun 2016 Preclinical trials in Bacterial infections in UK before June 2016 (unspecified route)
  • 16 Jun 2016 Antimicrobial activity and pharmacokinetics data in bacterial infections released by Redx Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top